NCT06672705 - Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderEBV-Related Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative DisorderRecurrent Polymorphic Post-Transplant Lymphoproliferative DisorderRefractory Monomorphic Post-Transplant Lymphoproliferative DisorderRefractory Polymorphic Post-Transplant Lymphoproliferative Disorder

Interventions

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo PET/CT

BIOLOGICAL

Epcoritamab

Given SC

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (2)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

63110

RECRUITING

Washington University, St Louis